Salvadori Maurizio, Bertoni Elisabetta
Maurizio Salvadori, Elisabetta Bertoni, Department of Transplantation, Careggi University Hospital, 50139 Florence, Italy.
World J Transplant. 2014 Dec 24;4(4):243-66. doi: 10.5500/wjt.v4.i4.243.
Innovative and exciting advances in the clinical science in solid organ transplantation continuously realize as the results of studies, clinical trials, international conferences, consensus conferences, new technologies and discoveries. This review will address to the full spectrum of news in transplantation, that verified by 2013. The key areas covered are the transplantation activity, with particular regards to the donors, the news for solid organs such as kidney, pancreas, liver, heart and lung, the news in immunosuppressive therapies, the news in the field of tolerance and some of the main complications following transplantation as infections and cancers. The period of time covered by the study starts from the international meetings held in 2012, whose results were published in 2013, up to the 2013 meetings, conferences and consensus published in the first months of 2014. In particular for every organ, the trends in numbers and survival have been reviewed as well as the most relevant problems such as organ preservation, ischemia reperfusion injuries, and rejections with particular regards to the antibody mediated rejection that involves all solid organs. The new drugs and strategies applied in organ transplantation have been divided into new way of using old drugs or strategies and drugs new not yet on the market, but on phase Ito III of clinical studies and trials.
随着研究、临床试验、国际会议、共识会议、新技术及新发现的成果，实体器官移植临床科学不断取得创新且令人振奋的进展。本综述将阐述截至2013年已证实的移植领域的全方位新闻。涵盖的关键领域包括移植活动，特别是供体方面；实体器官如肾脏、胰腺、肝脏、心脏和肺的相关新闻；免疫抑制治疗方面的新闻；免疫耐受领域的新闻以及移植后一些主要并发症如感染和癌症。该研究涵盖的时间段从2012年召开的国际会议（其结果于2013年发表）开始，直至2014年头几个月发表的2013年会议、研讨会及共识。尤其针对每个器官，回顾了数量和生存率的趋势以及最相关的问题，如器官保存、缺血再灌注损伤和排斥反应，特别是涉及所有实体器官的抗体介导排斥反应。器官移植中应用的新药和策略已分为使用旧药或策略的新方式以及尚未上市但处于临床研究和试验I期至III期的新药。
